IQVIA Holdings Files Second Quarter 10-Q Report With SEC
The healthcare data and analytics giant submitted its quarterly financial disclosure as investors await key Federal Reserve decisions and Q3 earnings in the fall.
Quarterly Filing Submitted
IQVIA Holdings Inc. (NYSE: IQV) filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on July 28, according to regulatory disclosures. The filing provides updated financial information for the healthcare data analytics and clinical research organization, which carries a market capitalization of approximately $41 billion.
The company's shares last traded at $247.56. The 10-Q filing represents a standard quarterly disclosure requirement for publicly traded companies, offering investors and analysts detailed financial statements and management discussion of business operations.
Recent Insider Activity
According to MarginX data, IQVIA has recorded recent stock-based compensation activity among its executive leadership. Carol J. Burt, John M. Leonard, and Colleen A. Goggins each received stock awards of 1,571 shares. These grants represent standard equity compensation arrangements common among publicly traded corporations to align executive interests with shareholder value.
Looking Ahead
Investors in IQVIA and the broader healthcare sector face several key dates on the calendar. The Federal Reserve is scheduled to announce its next rate decision and economic projections on September 16, 2026, which could influence valuations across growth-oriented sectors including healthcare technology and services.
MarginX data indicates that IQVIA is expected to report its third quarter 2026 results on October 28, 2026, coinciding with another FOMC rate decision the same day. This convergence of corporate earnings and monetary policy announcements may create heightened volatility for the stock as investors assess both company-specific performance and macroeconomic conditions.
IQVIA operates at the intersection of healthcare data analytics, technology solutions, and contract research services, providing critical infrastructure for pharmaceutical development and commercial operations. The company's quarterly disclosures offer insight into trends across drug development spending, healthcare data demand, and broader life sciences industry activity.
This article was generated by MarginX from public news on 2026-07-28. It is not investment advice.